iSpecimen Inc. (NASDAQ:ISPC – Get Free Report) traded down 9.5% during mid-day trading on Tuesday . The company traded as low as $1.32 and last traded at $1.33. 210,799 shares were traded during trading, a decline of 87% from the average daily volume of 1,645,295 shares. The stock had previously closed at $1.47.
Analysts Set New Price Targets
Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of iSpecimen in a research note on Friday, July 17th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company currently has an average rating of “Sell”.
Check Out Our Latest Research Report on iSpecimen
iSpecimen Stock Performance
iSpecimen (NASDAQ:ISPC – Get Free Report) last announced its quarterly earnings data on Friday, August 14th. The company reported ($0.98) EPS for the quarter. iSpecimen had a negative return on equity of 524.39% and a negative net margin of 2,445.40%.The firm had revenue of $0.15 million for the quarter.
iSpecimen Company Profile
iSpecimen, Inc (NASDAQ:ISPC) operates an online life sciences marketplace designed to connect researchers with human biological specimens and associated clinical data. The company’s platform streamlines the sourcing of biospecimens—such as plasma, serum, fresh and frozen tissue, saliva, urine and peripheral blood mononuclear cells (PBMCs)—by matching demand from pharmaceutical, biotechnology, diagnostic and academic organizations with supply from a wide network of clinical sites and biobanks.
Through its on-demand procurement model, iSpecimen provides customized specimen collection and fulfillment services that help accelerate research timelines and improve data quality.
See Also
- Five stocks we like better than iSpecimen
- Running on Empty: 3 Energy Plays for Europe’s Deep Freeze
- 3 Healthcare Stocks for 3 Stages of Life
- Curaleaf Tries To Roll Up Aurora In a Hostile Cannabis Bid
- MarketBeat’s Most Downgraded Stocks in Q3: 2 Look Cheap, 1 Looks Risky
Receive News & Ratings for iSpecimen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iSpecimen and related companies with MarketBeat.com's FREE daily email newsletter.
